IEO
Funder
69 Projects, page 1 of 14
assignment_turned_in ProjectFrom 2024Organizations:IEO, PAU, Institut de Génomique Fonctionnelle, Medical Faculty Mannheim, Osnabrück UniversityIEO,PAU,Institut de Génomique Fonctionnelle,Medical Faculty Mannheim,Osnabrück UniversityFunder: French National Research Agency (ANR) Project Code: ANR-23-NEU2-0004Funder Contribution: 262,185 EURAll Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=anr_________::0d86d8b75e848fcbfb14ba3ccdc03bc4&type=result"></script>'); --> </script>For further information contact us at helpdesk@openaire.euassignment_turned_in ProjectFrom 2019Organizations:Leipzig University, UNICANCER, Oncompass Medicine Hungary Kft, IEO, INSTITUT CURIE SECTION MEDICALE +1 partnersLeipzig University,UNICANCER,Oncompass Medicine Hungary Kft,IEO,INSTITUT CURIE SECTION MEDICALE,IBBLFunder: French National Research Agency (ANR) Project Code: ANR-18-PERM-0010Funder Contribution: 499,566 EURAll Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=anr_________::4c25e62e0d861d8c61bfe95751996a01&type=result"></script>'); --> </script>For further information contact us at helpdesk@openaire.euassignment_turned_in ProjectFrom 2019Organizations:INSB, Radboud university medical center, SickKids Hospital, IEO, Institute of Science and Technology Austria +2 partnersINSB,Radboud university medical center,SickKids Hospital,IEO,Institute of Science and Technology Austria,UAntwerp,IGHFunder: French National Research Agency (ANR) Project Code: ANR-18-RAR3-0005Funder Contribution: 249,966 EURAll Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=anr_________::56ab6267e91ed845271acb31d1d7aaca&type=result"></script>'); --> </script>For further information contact us at helpdesk@openaire.euassignment_turned_in ProjectFrom 2017Organizations:ISB-HMGU, RNM, IEO, Centre national de la recherche scientifique, CNRS, CNRS-FACULTE DE PHARMACIE DE LUNIVERSITE DE STRASBOURG +5 partnersISB-HMGU,RNM,IEO,Centre national de la recherche scientifique, CNRS,CNRS-FACULTE DE PHARMACIE DE LUNIVERSITE DE STRASBOURG,CCU,NOBEL PHARM ULKAR HOLDING A.S.,Institut National de la Recherche Medicale,Centre National De La Recherche Scientifique,MIRA INSTITUTE-UNIVERSITY OF TWENTE-THE NETHERLANDSFunder: French National Research Agency (ANR) Project Code: ANR-16-ECVD-0005Funder Contribution: 244,606 EURCardiac dysfunction leading to heart failure can result from anticancer drug-induced cardiotoxicity. It is the second cause of morbidity and mortality among cancer survivors, a group that is growing due to improved cancer treatments. No reliable early markers of drug-induced cardiotoxicity have been identified, and safe, effective drugs to prevent anticancer drug-induced cardiotoxicity are not available. Taking into account the extensive economic and social costs of this condition, it is imperative to develop both early cardiotoxicity markers and efficacious drugs to protect cancer patients against cardiotoxic anticancer drugs. The Cardio-Oncology consortium brings together cardiologists (D. Cardinale), cardiobiologists (C. Nebigil), oncologists (M.W. Chan), chemo-bioinformaticians (I. Tetko), stem cell cardiobiologists (R. Passier) and medicinal chemists (L. Désaubry & Ö. Reis). Together, the consortium aims to 1) develop cardio-protective therapeutics, including in silico, in vitro and in vivo testing, and benchmarking in mouse models and human stem cells, 2) validate and analyse predictive biomarkers of cardiotoxicity in European and Taiwanese cancer patients to detect early cardiac dysfunction and to define the distinctive etiopathogenetic features of cardiotoxicity. The Cardio-Oncology project will deliver biomarker candidates and cardio-protective drug candidates that can be further developed by pharmaceutical and diagnostic companies aiming to improve cancer care.
All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=anr_________::7ee5dfad549212f670b8a21c3dfa7ab8&type=result"></script>'); --> </script>For further information contact us at helpdesk@openaire.euassignment_turned_in ProjectFrom 2020Organizations:Institut Pasteur, IEO, ETH Zurich, CIUSSS du Centre-Ouest-de-l’Île-de-Montréal – Hôpital général juif - Lady Davis Institut, Helmholtz Association of German Research Centres +3 partnersInstitut Pasteur,IEO,ETH Zurich,CIUSSS du Centre-Ouest-de-l’Île-de-Montréal – Hôpital général juif - Lady Davis Institut,Helmholtz Association of German Research Centres,False,CIUSSS du Centre-Ouest-de-l’Île-de-Montréal – Hôpital général juif - Lady Davis Institut,MDCFunder: French National Research Agency (ANR) Project Code: ANR-19-NEUR-0007Funder Contribution: 199,931 EURAll Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=anr_________::c7902d23fec6219829fce9edda1e12b7&type=result"></script>'); --> </script>For further information contact us at helpdesk@openaire.eu
chevron_left - 1
- 2
- 3
- 4
- 5
chevron_right